ABVC BioPharma, Inc. Share Price
ABVCABVC BioPharma, Inc. Stock Performance
Open $1.25 | Prev. Close $1.21 | Circuit Range N/A |
Day Range $1.19 - $1.28 | Year Range $0.61 - $5.43 | Volume 1,342 |
Average Traded $1.22 |
ABVC BioPharma, Inc. Share Price Chart
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is headquartered in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
ABVC BioPharma, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
27-Feb-26 | $1.25 | $1.28 | +0.39% |
26-Feb-26 | $1.35 | $1.28 | -5.88% |
25-Feb-26 | $1.37 | $1.36 | -1.45% |
24-Feb-26 | $1.38 | $1.38 | -0.72% |
23-Feb-26 | $1.48 | $1.39 | -7.95% |
20-Feb-26 | $1.51 | $1.51 | +0.00% |
19-Feb-26 | $1.55 | $1.51 | -5.03% |